Laurus Labs Q2 FY27 Results: Net Profit Rises 126.7% To ₹442 Crore As Revenue Grows 33.4% And EBITDA Jumps 86%; Share Rises

Laurus Labs closed the September quarter of FY27 with a net profit of ₹442 crore, more than twice the ₹195 crore it earned in the same period last year. Revenue also moved higher, rising 33.5% to ₹2,206 crore.

Operating earnings saw an even bigger jump, with earnings before interest, tax, depreciation, and amortisation (EBITDA) climbing 86.3% to ₹749 crore. Alongside its quarterly results, the pharmaceutical company announced investments in two businesses and an interim dividend for shareholders.

Laurus Labs Share Price Rises After Q2 FY27 Results

Laurus Labs shares were trading at ₹2,337.10 on 30 October 2026, up 4.15% at 9:55 AM.

The numbers were better than market estimates. Analysts had pegged net profit at ₹354.1 crore and revenue at ₹2,109.5 crore. EBITDA was expected to come in at ₹644.4 crore, against the ₹750 crore reported by the company.

There was also a noticeable improvement in operating margins. EBITDA margin stood at 34% during the quarter, compared with 24.4% a year earlier. This means Laurus Labs retained a larger share of its revenue as operating earnings than it did in the corresponding quarter last year.

Which Two Companies Is Laurus Labs Acquiring?

One of the key announcements alongside the results was Laurus Labs' decision to acquire stakes in two businesses.

The first deal involves SI & C Resins Private Limited. Laurus Labs will acquire a 52% stake at a pre-money valuation of ₹30 crore, investing ₹32.5 crore. Once completed, SI&C will become a subsidiary. Laurus Labs has also kept the option of investing another ₹30 crore in the company if it needs additional funding.

SI&C makes polymer- and silica-based products used across the chemical, pharmaceutical and biotechnology industries.

The second acquisition is in Canada. Laurus Labs will purchase a 60% stake in Galenvs Sciences Inc. at a pre-money valuation of $3.5 million. The proposed investment is $3.75 million, split between a fresh infusion of $2.75 million and a $1 million purchase of shares from the founder.

Galenvs works on custom oligonucleotide synthesis and functional magnetic nanoparticle technologies, which have applications in diagnostics and therapeutics. Its subsidiary, Galenvs Solutions Inc., will also come under Laurus Labs as a step-down subsidiary.

Laurus Labs Announces ₹1 Interim Dividend

The company will pay ₹1 for every equity share held by investors. The board has set 6 November 2026 as the record date, so shareholders on the company's records on that day will be eligible. Laurus Labs expects to start crediting the dividend on or after 19 November 2026.

Also Read - Intel Q3 Results: Adjusted Earnings Beat Estimates As Data Centre And AI Revenue Surges 78%, But Weak Q4 Guidance Hits Shares